Roche teams with Oryzon in evolving epigenetics space

Save

Roche has bought the rights to Oryzon's class of lysine specific demethylase-1 (LSD1) inhibitors, of which the lead molecule ORY-1001 was granted orphan drug status in Europe in August last year as a treatment for acute myeloid leukemia (AML). Oryzon…